论文部分内容阅读
目的观察应用大剂量静脉铁剂治疗持续不卧床腹膜透析患者肾性贫血的有效性及安全性。方法 31例持续不卧床腹膜透析(PD)患者,采用足量低分子量右旋糖酐铁静脉滴注补铁,每次500mg,1周1～2次。观察治疗前及治疗8周后血红蛋白(Hb)、血细胞比容(Hct)、血清铁蛋白(SF)、转铁蛋白饱和度(TS)的变化。结果治疗8周后,患者Hb[(102.7±10.6)g/Lvs.(69.9±5.8)g/L]、Hct[(28.5±3.2)%vs.(19.7±4.2)%]、SF[(501.6±20.3)ng/mlvs.(215.8±15.3)ng/ml]及TS[(29.3±3.4)%vs.(11.4±4.5)%]较治疗前显著上升(P﹤0.05)。无严重不良反应发生。结论静脉输注大剂量低分子量右旋糖酐铁治疗PD患者缺铁性贫血安全、有效。
Objective To observe the effectiveness and safety of high-dose intravenous iron in the treatment of renal anemia in ambulatory peritoneal dialysis patients. Methods Thirty - one patients with continuous ambulatory peritoneal dialysis (PD) were treated with intravenous infusion of adequate low molecular weight iron dextran 500 mg once or twice a week for 1 week. The changes of hemoglobin (Hb), hematocrit (Hct), serum ferritin (SF) and transferrin saturation (TS) before and 8 weeks after treatment were observed. Results Hb [(102.7 ± 10.6) g / L vs (69.9 ± 5.8) g / L], Hct [(28.5 ± 3.2)% vs (19.7 ± 4.2)%], SF [ ± 20.3 ng / ml vs 215.8 ± 15.3 ng / ml and TS 29.3 ± 3.4% vs 11.4 ± 4.5%, respectively. No serious adverse reactions occurred. Conclusion Intravenous iron infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia in PD patients is safe and effective.